Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

DNA methylation signature predicts cancer response to demethylation agents from profiling diverse cancer cell lines
Wang, Xuewei , Vedell, Pete, Kocher, Jean‐Pierre , Sun, Zhifu , Vedell, Peter T.

Mayo Clinic

Cancer Communications | June 18, 2022 | Volume: 42 | Issue: 8 | Pages: 789-792

10.1002/cac2.12326 | PMID 35716010 Get It

Eosinophils protect against acetaminophen‐induced liver injury through cyclooxygenase‐mediated IL‐4/IL‐13 production
Xu, Long , Yang, Yang , Jiang, Jiali, Wen, Yankai , Jeong, Jong‐Min , Emontzpohl, Christoph , Atkins, Constance L. , Kim, Kangho , Jacobsen, Elizabeth A. , Wang, Hua , Ju, Cynthia, Atkins, Constance Lynn , Jacobsen, Elizabeth A , Wen, Yankai , Yang, Yang , Kim, Kangho

Mayo Clinic

Hepatology | June 17, 2022 | Volume: 77 | Issue: 2 | Pages: 456-465

10.1002/hep.32609 | PMID 35714036 Get It

Background and Aims: A better understanding of the underlying mechanism of acetaminophen (APAP)‐induced liver injury (AILI) remains an important endeavor to develop therapeutic approaches. Eosinophils have been detected in liver biopsies of patients with APAP overdose. We recently demonstrated a profound protective role of eosinophils against AILI; however, the molecular mechanism had not been elucidated. Approach and Results: In agreement with our previous data from experiments using genetic deletion of eosinophils, we found that depletion of eosinophils in wild‐type (WT) mice by an anti‐IL‐15 antibody resulted in exacerbated AILI. Moreover, adoptive transfer of eosinophils significantly reduced liver injury and mortality rate in WT mice. Mechanistic studies using eosinophil‐specific IL‐4/IL‐13 knockout mice demonstrated that these cytokines, through inhibiting interferon‐γ, mediated the hepatoprotective function of eosinophils. Reverse phase protein array analyses and in vitro experiments using various inhibitors demonstrated that IL‐33 stimulation of eosinophils activated p38 mitogen‐activated protein kinase (MAPK), and in turn, cyclooxygenases (COX), which triggered NF‐κB–mediated IL‐4/IL‐13 production. In vivo adoptive transfer experiments showed that in contrast to naive eosinophils, those pretreated with COX inhibitors failed to attenuate AILI. Conclusions: The current study revealed that eosinophil‐derived IL‐4/IL‐13 accounted for the hepatoprotective effect of eosinophils during AILI. The data demonstrated that the p38 MAPK/COX/NF‐κB signaling cascade played a critical role in inducing IL‐4/IL‐13 production by eosinophils in response to IL‐33.
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
Thompson, Kevin J. , Leon‐Ferre, Roberto A. , Zahrieh, David , Metzger, Filho Otto, Sikov, William M. , Liu, Minetta C. , Carter, Jodi M. , Klee, Eric W. , Weinshilboum, Richard M. , Wang, Liewei , Zahrieh, David M. , Ingle, James N. , Goetz, Matthew P , Kalari, Krishna R , Thompson, Kevin J , Carter, Jodi , Sinnwell, Jason P. , Suman, Vera J. , Asad, Sarah , Stover, Daniel G. , Carey, Lisa A. , Weinshilboum, Richard M. , Boughey, Judy C. , Couch, Fergus J. , Goetz, Matthew P. , Kalari, Krishna R.

Mayo Clinic

NAR Cancer | June 17, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/narcan/zcac018 | PMID 35734391 Get It

Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low overall survival rates and high molecular heterogeneity; therefore, few targeted therapies are available. The luminal androgen receptor (LAR) is the most consistently identified TNBC subtype, but the clinical utility has yet to be established. Here, we constructed a novel genomic classifier, LAR-Sig, that distinguishes the LAR subtype from other TNBC subtypes and provide evidence that it is a clinically distinct disease. A meta-analysis of seven TNBC datasets (n = 1086 samples) from neoadjuvant clinical trials demonstrated that LAR patients have significantly reduced response (pCR) rates than non-LAR TNBC patients (odds ratio = 2.11, 95% CI: 1.33, 2.89). Moreover, deconvolution of the tumor microenvironment confirmed an enrichment of luminal epithelium corresponding with a decrease in basal and myoepithelium in LAR TNBC tumors. Increased immunosuppression in LAR patients may lead to a decreased presence of cycling T-cells and plasma cells. While, an increased presence of myofibroblast-like cancer-associated cells may impede drug delivery and treatment. In summary, the lower levels of tumor infiltrating lymphocytes (TILs), reduced immune activity in the micro-environment, and lower pCR rates after NAC, suggest that new therapeutic strategies for the LAR TNBC subtype need to be developed.
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)
Seegobin, Karan , Li, Zhuo , Wang, Jing , Jiang, Liuyan , Kuhlman, Justin J. , Menke, David M. , Li, Ke , Kharfan‐Dabaja, Mohamed A. , Ayala, Ernesto , Nowakowski, Grzegorz S. , Johnston, Patrick B. , Thompson, Carrie A. , Ansell, Stephen M. , Alhaj Moustafa, Muhamad, Kuhlman, Justin , Menke, David, Kharfan-Dabaja, Mohamed A , Iqbal, Madiha , Habermann, Thomas , Witzig, T.E. , Thompson, Carrie, Ansell, Stephen M , Moustafa, Muhamad Alhaj , Majeed, Umair , Iqbal, Madiha , Habermann, Thomas M. , Witzig, Thomas E. , Tun, Han W.

Mayo Clinic

American Journal of Hematology | June 17, 2022 | Volume: 97 | Issue: 9 | Pages: 1150-1158

10.1002/ajh.26635 | PMID 35713565 Get It

Abstract Intravascular lymphoma (IVL) is a rare extranodal non‐Hodgkin lymphoma. We performed a retrospective analysis of 55 IVL patients who were treated at our institution 2003–2018. Median age at diagnosis was 68 years, and 64% were males. The most frequent presenting symptoms were skin rash 43% and weight loss 30%. MRI brain on IVL patients with CNS involvement (CNS‐IVL) showed multifocal involvement in 76% (13/17). 89% (17/19) of non‐CNS‐IVL patients with abnormal FDG‐PET had biopsy of an avid lesion resulting in definitive diagnosis. The top diagnostic biopsy site was the bone marrow (45%). 56% had multiorgan involvement. Based on CNS involvement, 36.5% (20/55) had CNS‐IVL and 63.5% (35/55) had non‐CNS‐IVL. CNS‐IVL group consists of clinically isolated CNS involvement (CNS‐only IVL) (22%;12/55) and mixed clinical CNS and peripheral site involvement (M‐IVL) (14.5%; 8/55). Non‐CNS‐IVL group consists of clinically isolated skin involvement (skin‐only IVL) (9%; 5/55) and peripheral IVL with or without skin involvement (P‐IVL); (54.5%; 30/55). Skin involvement was predominantly in the lower extremities. Pathologically, 89% (48/54) were B‐cell IVL. Rituximab + high‐dose methotrexate‐based regimen were used in 75% (12/16) of CNS‐IVL patients and RCHOP in 60% (17/28) of non‐CNS‐IVL patients. Estimated 5‐year progression free survival (PFS) and overall survival (OS) for the entire cohort were 38.6% and 52%, respectively. Skin‐only IVL was associated with excellent survival. Platelet count <150x10 9 /L, age > 60Y, and treatment without Rituximab were poor prognostic factors. Further research is necessary to identify novel therapies.
eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma
Wang, Xiaoyu , Gharahkhani, Puya , Levine, David , Fitzgerald, Rebecca C. , Corley, Douglas A. , Risch, Harvey A. , Bernstein, Leslie , Chow, Wong‐Ho , Onstad, Lynn , Shaheen, Nicholas J. , Lagergren, Jesper , Hardie, Laura J. , Wu, Anna H. , Liu, Geoffrey , Anderson, Lesley , Iyer, Prasad G. , Gammon, Marilie D. , Caldas, Carlos , Ye, Weimin , Barr, Hugh , Harrison, Rebecca , Watson, R.G. Peter , Attwood, Stephen , Chegwidden, Laura , Love, Sharon , MacDonald, David , Prenen, Hans , Ott, Katja , Lang, Hauke , Mayershofer, Rupert , Knapp, Michael , Veits, Lothar , Gerges, Christian , Weismüller, Josef , Reeh, Matthias , Nöthen, Markus M. , Izbicki, Jakob R. , Manner, Hendrik , Neuhaus, Horst , Böhmer, Anne C. , Hölscher, Arnulf H. , Anders, Mario , Pech, Oliver , Schumacher, Brigitte , Schmidt, Claudia , Noder, Tania , Lorenz, Dietmar , Vieth, Michael , May, Andrea , Kreuser, Nicole , Becker, Jessica , Ell, Christian , Tomlinson, Ian , Palles, Claire , Whiteman, David C. , MacGregor, Stuart , Schumacher, Johannes , Vaughan, Thomas L. , Buas, Matthew F. , Dai, James Y. , Levine, David M , Gockel, Ines , Corley, Douglas A , Risch, Harvey A , Bernstein, Leslie , Chow, Wong-Ho , Onstad, Lynn , Shaheen, Nicholas J , Lagergren, Jesper , Hardie, Laura J , Wu, Anna H. , Pharoah, Paul D P , Liu, Geoffrey , Anderson, Lesley A , Iyer, P G , Caldas, Carlos , Ye, Weimin , Barr, Hugh , Moayyedi, Paul , Harrison, Rebecca , Watson, R G Peter , Attwood, Stephen , Chegwidden, Laura , Love, Sharon B , MacDonald, David , deCaestecker, John , Prenen, Hans , Ott, Katja , Moebus, Susanne , Venerito, Marino , Lang, Hauke , Mayershofer, Rupert , Knapp, Michael , Veits, Lothar , Gerges, Christian , Weismüller, Josef , Reeh, Matthias , Nöthen, Markus M , Izbicki, Jakob R , Manner, Hendrik , Neuhaus, Horst , Rösch, Thomas , Böhmer, Anne C , Hölscher, Arnulf H , Anders, Mario , Pech, Oliver , Schumacher, Brigitte , Schmidt, Claudia , Schmidt, Thomas , Noder, Tania , Lorenz, Dietmar , Vieth, Michael , May, Andrea , Hess, Timo , Kreuser, Nicole , Becker, Jessica , Ell, Christian , Tomlinson, Ian , Palles, Claire , Jankowski, Janusz A , Whiteman, David C , MacGregor, Stuart , Schumacher, Johannes , Vaughan, Thomas L , Buas, Matthew F , Dai, James Y , Gharahkhani, Puya , Pharoah, Paul D.P. , Moayyedi, Paul , Caestecker, John de , Moebus, Susanne , Hess, Timo , Jankowski, Janusz

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2022 | Volume: 31 | Issue: 9 | Pages: 1735-1745

10.1158/1055-9965.epi-22-0096 | PMID 35709760 Get It

Abstract Background: Over 20 susceptibility single-nucleotide polymorphisms (SNP) have been identified for esophageal adenocarcinoma (EAC) and its precursor, Barrett esophagus (BE), explaining a small portion of heritability. Methods: Using genetic data from 4,323 BE and 4,116 EAC patients aggregated by international consortia including the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), we conducted a comprehensive transcriptome-wide association study (TWAS) for BE/EAC, leveraging Genotype Tissue Expression (GTEx) gene-expression data from six tissue types of plausible relevance to EAC etiology: mucosa and muscularis from the esophagus, gastroesophageal (GE) junction, stomach, whole blood, and visceral adipose. Two analytical approaches were taken: standard TWAS using the predicted gene expression from local expression quantitative trait loci (eQTL), and set-based SKAT association using selected eQTLs that predict the gene expression. Results: Although the standard approach did not identify significant signals, the eQTL set–based approach identified eight novel associations, three of which were validated in independent external data (eQTL SNP sets for EXOC3, ZNF641, and HSP90AA1). Conclusions: This study identified novel genetic susceptibility loci for EAC and BE using an eQTL set–based genetic association approach. Impact: This study expanded the pool of genetic susceptibility loci for EAC and BE, suggesting the potential of the eQTL set–based genetic association approach as an alternative method for TWAS analysis.
Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
Hirano, Fumiya, Kaneko, Katsumi , Tamura, Hideto , Wang, Shengdian , Rietz, Cecilia, Flies, Dallas B. , Lau, Julie S., Zhu, Gefeng, Tamada, Koji , Kaneko, Katsumi, Dong, Haidong , Ichikawa, Masao, Chen, Lieping

Mayo Clinic

Cancer Research | June 16, 2022 | Volume: 65 | Issue: 3 | Pages: 1089-1096

10.1158/0008-5472.1089.65.3 Get It

Abstract Contemporary approaches for vaccination and immunotherapy are often capable of eliciting strong T-cell responses against tumor antigens. However, such responses are not parallel to clinical tumor regression. The development of evasion mechanisms within tumor microenvironment may be responsible for poor therapeutic responses. We report here that constitutive or inducible expression of B7-H1, a B7 family molecule widely expressed by cancers, confers resistance to therapeutic anti-CD137 antibody in mice with established tumors. The resistance is accompanied with failure of antigen-specific CD8+ CTLs to destroy tumor cells without impairment of CTL function. Blockade of B7-H1 or PD-1 by specific monoclonal antibodies could reverse this resistance and profoundly enhance therapeutic efficacy. Our findings support that B7-H1/PD-1 forms a molecular shield to prevent destruction by CTLs and implicate new approaches for immunotherapy of human cancers.
Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies
Zhan, Shipeng, Du, Heyue , Li, Jing , Aertgeerts, Bert , Li, Ling , Su, Na , Vandvik, Per Olav , Li, Sheyu , Riaz, Irbaz, Li, Sheyu , Wang, Yang , Khan, Safi U. , Guyatt, Gordon , Hao, Qiukui , Bekkering, Geertruida Elsiena , Delvaux, Nicolas , Riaz, Irbaz Bin , Tian, Haoming

Mayo Clinic

BMJ Medicine | June 16, 2022 | Volume: 1 | Issue: 1 | Pages: e000134

10.1136/bmjmed-2022-000134 | PMID 36936552 Get It

Objective To determine the harms of ezetimibe in people who need lipid-lowering treatment. Design Systematic review and meta-analysis. Data sources Randomised controlled trials and cohort studies. Eligibility criteria for selecting studies Studies comparing ezetimibe with placebo, standard care, or other lipid-lowering agents in people who need lipid-lowering treatment with a follow-up duration of at least six months (or 24 weeks). The relative effects for potential harms of ezetimibe were pooled by use of random effect pairwise meta-analyses for randomised controlled trials and the evidence from observational studies was narratively summarised. The certainty of evidence was assessed using the Grading of Recommendation Assessment, Development, and Evaluation. Results 48 randomised controlled trials with 28 444 participants (median follow-up 34 weeks, range 24-312 weeks) and four observational studies with 1667 participants (median follow-up 282 weeks, range 72-400 weeks) were included. The meta-analyses of randomised trials showed moderate to high certainty that ezetimibe was not associated with cancer (relative risk 1.01; 95% confidence interval 0.92 to 1.11), fractures (0.90; 0.74 to 1.10), discontinuation due to any adverse event (0.87; 0.74 to 1.03), gastrointestinal adverse events leading to discontinuation (1.34; 0.58 to 3.08), myalgia or muscular pain leading to discontinuation (0.82; 0.51 to 1.33), neurocognitive events (1.48; 0.58 to 3.81), or new-onset diabetes (0.88; 0.61 to 1.28). The narrative analysis of observational studies provided consistent findings. No credible subgroup effects were identified for the harm outcomes, including shorter versus longer follow-up duration of trials. Conclusions Ezetimibe results in little to no difference in adverse events or other undesirable effects compared with placebo, usual care or other lipid-lowering agents. Review registration PROSPERO CRD42020187437.
Abstract 770: Multiregional imaging and genomic analysis in high-grade IDH-mutant astrocytoma identifies intratumor subclones with aggressive features
Ensign, Shannon P. Fortin , Sereduk, Christopher, Singleton, Kyle , Eschbacher, Jennifer , Mrugala, Maciej , Porter, Alyx B. , Smith, Kris A. , Swanson, Kamala, Wang, Junwen , Semmineh, Nathenael, Quarles, Christopher, Lasorella, Anna , Swanson, Kristin R. , Hu, Leland , Ensign, Shannon P. Fortin , Swanson, Kristin R , Wang, Junwen , D’Angelo, Fulvio , Caruso, Francesca Pia , Sereduk, Chris , Mazza, Gina L , Bendok, Bernard R. , Zimmerman, Richard, Nakaji, Peter , Ceccarelli, Michele , Iavarone, Antonio , Tran, Nhan L.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 770-770

10.1158/1538-7445.am2022-770 Get It

Abstract High-grade gliomas represent the most common type of primary adult malignant brain tumor historically diagnosed and graded from histologic criteria alone. Gliomas harboring isocitrate dehydrogenase (IDH) 1 or 2 mutations, which are present in more than 80% of World Health Organization (WHO) grade 2 or 3 tumors, portend a favorable prognosis as compared to IDH-wildtype tumors. However, recent molecular profiling has identified the presence of additional alterations in these lower grade tumors that transform the biology toward an aggressive high-grade phenotype clinically that are independent of histologic grading and confer a worse clinical prognosis. Of these, the loss of CDKN2A/B is the strongest implicated alteration and is sufficient to define a grade 4 tumor in IDH-mutant astrocytomas regardless of histologic appearance. However, there remain no effective therapies targeted at molecular subgroups in aggressive gliomas to date. Here we have profiled the intratumoral heterogeneity via whole exome and RNA sequencing and copy number alteration analysis within a cohort of de-identified IDH-mutant astrocytoma patient tumors collected through the Mayo Clinic and Barrow Neurological Institute (BNI) biorepositories to determine the spatial evolution of aggressive molecular features. Within this cohort we have collected 42 image-localized intratumoral biopsy specimens representing 13 IDH-mutant patient tumors. We identified 11 biopsies from 3 tumors that harbored loss of CDKN2A/B which included 1 tumor that displayed intratumoral heterogeneity of CDKN2A/B expression across subclones. We performed an unsupervised cluster analysis to profile the transcriptional signatures in IDH-mutant astrocytomas across both differential CDKN2A/B status and tumor geographic location comparing contrast enhancing versus non-enhancing regions, and we analyzed the MRI features in IDH-mutant tumors across CDKN2A/B status. We found that tumors with CDKN2A/B alteration demonstrated lower signal intensity on delayed post-contrast T2*W images, which could represent lower pre-contrast T2*, unique contrast agent kinetics, or dissimilar diffusion properties related to increased cellular density and/or greater heterogeneity of cell size. Interestingly, we uncovered spatial heterogeneity of additional molecular drivers of high-grade glioma including KRAS, MYCN, and PDGFRA. While EGFR alterations are rarely reported in IDH-mutant tumors, we identified one treatment naïve patient tumor that harbored EGFR alteration only in the contrast non-enhancing region. Based on this work we propose there is early spatial evolution of aggressive tumor subclones prior to primary tumor diagnosis, and multiregional molecular profiling may better inform tumor biology and predict therapeutic strategies in IDH-mutant astrocytomas. Citation Format: Shannon P. Fortin Ensign, Fulvio D'Angelo, Francesca P. Caruso, Christopher Sereduk, Kyle Singleton, Jennifer Eschbacher, Gina Mazza, Maciej Mrugala, Alyx Porter, Bernard Bendok, Richard Zimmerman, Kris Smith, Peter Nakaji, Kamala Swanson, Junwen Wang, Nathenael Semmineh, Christopher Quarles, Anna Lasorella, Kristin Swanson, Michele Ceccarelli, Antonio Iavarone, Leland Hu, Nhan L. Tran. Multiregional imaging and genomic analysis in high-grade IDH-mutant astrocytoma identifies intratumor subclones with aggressive features [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 770.
Abstract CT215: LB1901: A phase 1, open-label, multicenter, multicohort study of CD4-targeted chimeric antigen receptor T cells (CD4-CAR-T) in relapsed or refractory T-cell lymphoma (TCL)
lyer, Swaminathan P., Maloney, David G. , Wang, Chuan , Liang, Zhiyin, Castro, Henry, Pacaud, Lida , Bennani, N. Nora , Huen, Auris , Akram, Muhammad , Kim, Soo‐Jeong , Hamadani, Mehdi

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: CT215-CT215

10.1158/1538-7445.am2022-ct215 Get It

Abstract Background: Disease relapse is common with peripheral T-cell lymphomas (PTCL) or cutaneous T-cell lymphomas (CTCL). Adoptive immunotherapy with CD19 directed CAR-T cells is a standard option for B cell lymphoid malignancies in the relapsed setting. This study assesses the safety and preliminary efficacy of CD4 targeting autologous CAR-T, LB1901, in patients (pts) with CD4+ relapsed or refractory (R/R) TCL. A pre-clinical study showed LB1901 exhibited potent anti-tumor activity without off-target effects (Zeng 2021). Methods: This is a phase 1, open-label, multicenter, multicohort study of LB1901 (NCT04712864; currently enrolling). Eligible pts are ≥18 years with histologically confirmed CD4+ PTCL-NOS (not otherwise specified); or CD4+ AITL (angioimmunoblastic T-cell lymphoma); or CD4+ CTCL (either MF [mycosis fungoides] or SS [Sézary syndrome]). In Part A (dose escalation), pts with SS must have ≤2,000 circulating Sézary cells/µL to ensure safety of pts with higher disease burden. In Part B, pts with &gt;2,000 Sézary cells/µL is allowed. CD4 expressed on tumor cells must be confirmed within 3 months prior to apheresis. Other inclusion criteria include: R/R disease with ≥2 prior lines of systemic antineoplastic therapy; for pts with PTCL-NOS or AITL, ≥1 measurable lesion according to IWG Response Criteria (Cheson 2014) and for pts with CTCL, ≥stage IIB on TNMB-ISLC/EORTC staging system; identified HSCT donor available prior to enrollment (in the event of severe recurrent infections and prolonged lymphopenia for which pt may need an allogeneic HSCT as a safety rescue); and ECOG status of 0 or 1. Response will be evaluated based on IWG response criteria for PTCL and Global Composite Response for CTCL (Olsen 2007). The study will be conducted in 2 parts (Part A: dose escalation and Part B: dose expansion). Three dose levels (0.3 X 106, 1.0 X 106, and 3.0 X 106 CAR+ viable T cells/kg) will be evaluated (N=3-6 for each dose level) with an optional dose level minus 1 (0.1 X 106 CAR+ viable T cells/kg). Part B will include 2 cohorts, PTCL and CTCL (N=12-20 for each), after the recommended dose for expansion (RDE) has been identified in Part A. Enrolled pts will undergo apheresis for PBMC collection. LB1901 will be manufactured from autologous CD8+ T cells. Pts may receive optional bridging therapy and receive lymphodepleting chemotherapy with fludarabine 30mg/m2/day and cyclophosphamide 300mg/m2/day (Flu-Cy), for 3 days followed by LB1901. Primary endpoints are incidence, duration, and severity of AEs and laboratory abnormalities (Parts A and B) and DLT at each dose level (Part A). Secondary endpoints include overall response rate; duration of response; CAR-positive T cell counts and CAR transgene level in blood; and presence of anti-CAR antibody response. Exploratory endpoints include preliminary efficacy, pharmacokinetics, and CD4+ T cell counts. Citation Format: Swaminathan P. lyer, David G. Maloney, Nora Bennani, Auris Huen, Muhammad Akram, Soo Kim, Chuan Wang, Zhiyin Liang, Henry Castro, Lida Pacaud, Mehdi Hamadani. LB1901: A phase 1, open-label, multicenter, multicohort study of CD4-targeted chimeric antigen receptor T cells (CD4-CAR-T) in relapsed or refractory T-cell lymphoma (TCL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT215.
Abstract LB564: (±) 14,15-epoxyeicosatrienoic acid induces hallmark ER and MYC gene expression and associated ER and c-Myc nuclear translocation in ER+/HER2- breast cancer cells
Lei, Jianxun, Guo, Zhijun , Cervantes, Paloma, Hawse, John R. , Wang, Jinhua , Molina-Vega, Julissa , Jayaraman, Swaathi , Perez, Carlos, Abrahante, Juan E. , Tang, Xiaojia , Kalari, Krishna R. , Falck, John Russell , Lange, Carol Ann , Goetz, Matthew P. , Potter, David A.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: LB564-LB564

10.1158/1538-7445.am2022-lb564 Get It

Abstract While epoxyeicosatrienoic acids (EETs) have been implicated in breast cancer growth and progression, less is known about their effects on oncogene transcription. We have previously found that the oncogenic regioisomer (±)14,15-EET drives mitochondrial respiration, ATP synthesis, and proliferation of ER+/HER2- breast cancer cells [Cell Chem Biol. 2017 Oct 19;24(10):1259-1275]. RNAseq analysis was performed (5 replicates per condition) on serum starved (16 hours) MCF-7 cells which were then treated with (±)14,15-EET or vehicle (2 hours; serum and phenol red free medium without estradiol). Using gene set enrichment analysis (GSEA), we found that (±)14,15-EET activated an estrogen receptor alpha (ER) hallmark early response gene set and synchronously activated a MYC hallmark gene set. With activation of the MYC hallmark gene set, c-Myc gene expression was also induced at 2 hours (3.99-fold; P=2.3 x 10-17; FDR=2.8 x 10-14). These data suggest an alternative pathway for activation of estrogen and MYC regulated genes in the absence of estradiol. The 15 genes most transcriptionally activated by (±)14,15-EET at 2 hours were: VMP1, ZFP36, JUNB, FOS, IER3, EGR1, IER5L, ELF3, JUN, NR4A1, HES1, DUSP1, MYC, TOB1, and CITED2 [fold change range: 3.25 (CITED2) to 90.5 (FOS); all P&lt; 2.86 x 10-17; all FDR &lt; 3.03 x 10-14]. The ER regulated genes most transcriptionally activated (&gt;1.5 fold) were: IER3, TOB1, AREG, CISH, KCNMB3, and PDK4 (fold change range: 1.77 to 4.35; P= 1.74 x 10-18 to 1.35 x 10-5; FDR=5.54 x 10-15 to 6.4 x 10-4). The MYC regulated genes most transcriptionally activated (&gt; 1.5-fold change) were EIF4A1 (fold change= 2.37; P=1.0 x 10-7; FDR=1.33 x 10-5), IRF9 (fold change=1.58; P=0.0044; FDR= 0.026), and FOSL1 (fold change=1.51; P=0.008; FDR=0.04). Supporting the hypothesis of (±)14,15-EET activation of ER-regulated transcription, (±)14,15-EET promoted nuclear translocation of ER at 1 hour measured by DAPI normalized immunofluorescence [MCF-7 nuclear ER increase of 1.66-fold (P=0.031); ZR75-1 nuclear ER increase of 1.77-fold (P=0.015)]. Supporting the hypothesis of (±)14,15-EET activation of MYC-regulated transcription, (±)14,15-EET treatment promoted nuclear translocation of c-Myc with MCF-7 cells exhibiting a 1.22-fold increase at 2 hours (P=0.002). (±)14,15-EET also promoted nuclear translocation of FITC-70 kDa dextran with MCF-7 cells exhibiting an increase of 1.35-fold at 1 hour (P=0.029). These data suggest that (±)14,15-EET can induce an estradiol-like immediate early gene response in ER+/HER2- breast cancer cells correlating with c-Myc activation. In summary, while the effect of (±)14,15-EET on nuclear translocation may be partially cargo agnostic, (±)14,15-EET promotes ER and c-Myc nuclear translocation and associated transcription, mimicking a tandem hormonal and growth factor response. Citation Format: Jianxun Lei, Zhijun Guo, Julissa Molina-Vega, Paloma Cervantes, Swaathi Jayaraman, John R. Hawse, Carlos Perez, Juan Abrahante, Xiaojia Tang, Krishna Kalari, Jinhua Wang, John R. Falck, Carol Lange, Matthew P. Goetz, David Potter. (±) 14,15-epoxyeicosatrienoic acid induces hallmark ER and MYC gene expression and associated ER and c-Myc nuclear translocation in ER+/HER2- breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB564.